Olanzapine/Samidorphan (Lybalvi) in Palliative Care: A Case Report on Medication Reconciliation,Risk-Benefit Analysis,and Psychiatric Co-Management in an Outpatient Supportive Oncology Clinic
Restricted accessResearch articleFirst published online 2025
Olanzapine/Samidorphan (Lybalvi) in Palliative Care: A Case Report on Medication Reconciliation,Risk-Benefit Analysis,and Psychiatric Co-Management in an Outpatient Supportive Oncology Clinic
Patients with cancer have a high rate of comorbid psychiatric disorders. While the exact prevalence of comorbid bipolar I disorder and cancer is unknown, given the worse health outcomes associated with siloed specialist care, increased knowledge of the co-management of patients with cancer and bipolar I disorder is needed in palliative care. This case highlights a need for awareness regarding the specific combination of olanzapine and samidorphan (Lybalvi), approved in 2021 for the management of bipolar I disorder. Samidorphan, an opioid antagonist, mitigates the metabolic side effects of olanzapine. Notably, patients with comorbid bipolar I disorder and cancer often have both significant anorexia and pain, making samidorphan less desirable, as, in addition to mitigating metabolic side effects, it can limit the efficacy of analgesia from opioids. A recommendation of transitioning to olanzapine only is discussed.
Get full access to this article
View all access options for this article.
References
1.
MitchellAJ, ChanM, BhattiH, et al.Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies. Lancet Oncol2011;12(2):160–174; doi: 10.1016/S1470-2045(11)70002-X
2.
SingerS, Das-MunshiJ, BrählerE. Prevalence of mental health conditions in cancer patients in acute care–a meta-analysis. Ann Oncol2010;21(5):925–930; doi: 10.1093/annonc/mdp515
3.
MehnertA, BrählerE, FallerH, et al.Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol2014;32(31):3540–3546; doi: 10.1200/JCO.2014.56.0086
RasicDT, BelikSL, BoltonJM, et al.Cancer, mental disorders, suicidal ideation and attempts in a large community sample. Psychooncology2008;17(7):660–667; doi: 10.1002/pon.1292
6.
DekkerJ, BraamseA, van LindeME, et al.One in three patients with cancer meets the criteria for mental disorders: What does that mean? J Clin Oncol2015;33(25):2826–2828; doi: 10.1200/JCO.2015.61.9460
7.
SuppliNP, JohansenC, ChristensenJ, et al.Increased risk for depression after breast cancer: A nationwide population-based cohort study of associated factors in Denmark, 1998–2011. J Clin Oncol2014;32(34):3831–3839; doi: 10.1200/JCO.2013.54.0419
8.
MartinssonL, WestmanJ, HällgrenJ, et al.Lithium treatment and cancer incidence in bipolar disorder. Bipolar Disord2016;18(1):33–40; doi: 10.1111/bdi.12361
9.
AnmellaG, FicoG, LotfalianyM, et al.Risk of cancer in bipolar disorder and the potential role of lithium: International collaborative systematic review and meta-analyses. Neurosci Biobehav Rev2021;126:529–541; doi: 10.1016/j.neubiorev.2021.03.034
10.
GlasdamS, HybholtL, StjernswärdS. Experiences of everyday life among individuals with co-existence of serious mental illness and cancer-a qualitative systematic literature review. Healthcare (Basel)2023;11(13):1897; doi: 10.3390/healthcare11131897
11.
Kadan-LottickNS, VanderwerkerLC, BlockSD, et al.Psychiatric disorders and mental health service use in patients with advanced cancer: A report from the coping with cancer study. Cancer2005;104(12):2872–2881; doi: 10.1002/cncr.21532
12.
NakashO, LevavI, Aguilar-GaxiolaS, et al.Comorbidity of common mental disorders with cancer and their treatment gap: Findings from the World Mental Health Surveys. Psychooncology2014;23(1):40–51; doi: 10.1002/pon.3372
13.
ShalevD, DochertyM, Spaeth-RubleeB, et al.Bridging the behavioral health gap in serious illness care: Challenges and strategies for workforce development. Am J Geriatr Psychiatry2020;28(4):448–462; doi: 10.1016/j.jagp.2019.09.003
YildizA, SiafisS, MavridisD, et al.Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: A systematic review and network meta-analysis. Lancet Psychiatry2023;10(9):693–705; doi: 10.1016/S2215-0366(23)00199-2
16.
SandhyaL, Devi SreenivasanN, GoenkaL, et al.Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. J Clin Oncol2023;41(14):2617–2627; doi: 10.1200/JCO.22.01997
17.
NavariRM, PywellCM, Le-RademacherJG, et al.Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: A randomized pilot trial. JAMA Oncol2020;6(6):895–899; doi: 10.1001/jamaoncol.2020.1052
18.
BosnjakSM, DimitrijevicJ, DjordjevicF. Cancer and chemotherapy-induced nausea and vomiting: A focus on olanzapine. Curr Opin Support Palliat Care2016;10(2):180–188; doi: 10.1097/SPC.0000000000000206
19.
NakagawaN, SuzukiM. Efficacy of olanzapine for symptom relief in cancer patients. J Pain Palliat Care Pharmacother2022;36(4):216–222; doi: 10.1080/15360288.2022.2126059
20.
MonahanC, McCoyL, PowellJ, GumsJG. Olanzapine/Samidorphan: New drug approved for treating bipolar I disorder and schizophrenia. Ann Pharmacother2022;56(9):1049–1057; doi: 10.1177/10600280211070330
21.
McIntyreRS, CitromeL, CummingsH, et al.Opioid antagonism mitigates antipsychotic-associated weight gain: Focus on olanzapine. CNS Spectr2023;28(3):288–299; doi: 10.1017/S1092852922000116
22.
CorraoMM, NelsonLA. Olanzapine/Samidorphan: A new combination treatment for schizophrenia and bipolar I disorder intended to reduce weight gain. CNS Drugs2022;36(6):605–616; doi: 10.1007/s40263-022-00923-3
23.
CitromeL, GrahamC, SimmonsA, et al.An evidence-based review of OLZ/SAM for treatment of adults with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat2021;17:2885–2904; doi: 10.2147/NDT.S313840
24.
SakamotoS, DeguchiY, UchidaS, et al.Prolonged extrapyramidal symptoms induced by long‐term, intermittent administration of low‐dose olanzapine along with metoclopramide for emesis: A case report. Neuropsychopharmacol Rep2022;42(3):380–383; doi: 10.1002/npr2.12277
25.
MichnaE, BlonskyER, SchulmanS, et al.Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: A randomized controlled study. J Pain2011;12(5):554–562; doi: 10.1016/j.jpain.2010.11.008
26.
QianY, HuangZ, WangG, et al.Low-dose naloxone for prophylaxis of sufentanil-induced choking and postoperative nausea and vomiting. Front Pharmacol2022;13:1050847; doi: 10.3389/fphar.2022.1050847
27.
PietersBJ, AndersonJT, PriceN, et al.Low-dose versus high-dose postoperative naloxone infusion combined with patient-controlled analgesia for adolescent idiopathic scoliosis surgery: A randomized controlled trial. Spine Deform2018;6(4):430–434; doi: 10.1016/j.jspd.2018.01.005
28.
LinY, MiaoZ, WuY, et al.Effect of low dose naloxone on the immune system function of a patient undergoing video-assisted thoracoscopic resection of lung cancer with sufentanil controlled analgesia—a randomized controlled trial. BMC Anesthesiol2019;19(1):236; doi: 10.1186/s12871-019-0912-6
29.
ComerSD, SullivanMA, VosburgSK, et al.Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine‐maintained intravenous heroin abusers. Addiction2010;105(4):709–718; doi: 10.1111/j.1360-0443.2009.02843.x
30.
HickeyTR, HenryJT, EdensEL, et al.Perioperative management of extended-release buprenorphine. J Addict Med2023;17(1):e67–e71; doi: 10.1097/ADM.0000000000001024
31.
MurrayJP, PucciG, WeyerG, et al.Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: A retrospective case series. Addict Sci Clin Pract2023;18(1):38; doi: 10.1186/s13722-023-00392-z
32.
PatelKV, SahniS, TaylorLF. Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: A case report. J Osteopath Med2023;123(1):1–5; doi: 10.1515/jom-2022-0075
ChambersA, PattonJ, WillsBK. Precipitated opioid withdrawal in a patient started on olanzapine/samidorphan. Am J Emerg Med2024;79:230.e1–230.e2; doi: 10.1016/j.ajem.2024.03.027
35.
EigenbergerP, DesanP, CaroMA. A case of opioid withdrawal precipitated by samidorphan/olanzapine in a patient taking buprenorphine/naloxone. J Acad Consult Liaison Psychiatry2023;64(1):94–95; doi: 10.1016/j.jaclp.2022.09.004
36.
WarstadtNM, SchmitzZP, SoghoianSE. Olanzapine/samidorphan precipitated opioid withdrawal in a patient taking transdermal fentanyl. Clin Toxicol (Phila)2022;60(7):891–892; doi: 10.1080/15563650.2022.2049286
37.
HeL, ShenM, ZhangL, et al.A pharmacovigilance study of olanzapine/samidorphan based on FDA Adverse Event Reporting System (FAERS). BMC Pharmacol Toxicol2025;26(1):39; doi: 10.1186/s40360-025-00869-4
38.
PoonIO, AjewoleV, BraunUK. A review of olanzapine in the treatment of cancer anorexia-cachexia syndrome. Pharmacy (Basel)2024;12(1):34; doi: 10.3390/pharmacy12010034
39.
ŠoukalováZ. Olanzapine in oncology palliative care. Klin Onkol2022;35(4):276–283; doi: 10.48095/ccko2022276
40.
PraharajSK, JanaAK, GoyalN, SinhaVK. Metformin for olanzapine‐induced weight gain: A systematic review and meta‐analysis. Br J Clin Pharmacol2011;71(3):377–382; doi: 10.1111/j.1365-2125.2010.03783.x
41.
KaziB, RumaniI, KaziMNC, GaikwadPM. Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk. Curr Probl Cancer Case Rep2025;17:100345; doi: 10.1016/j.cpccr.2024.100345
42.
Meyer-JuncoL. Time to deprescribe: A Time-Centric model for deprescribing at end of life. J Palliat Med2021;24(2):273–284; doi: 10.1089/jpm.2020.0430
43.
ThompsonJ. Deprescribing in palliative care. Clin Med (Lond)2019;19(4):311–314; doi: 10.7861/clinmedicine.19-4-311
44.
LundbyC, NielsenM, SimonsenT, et al.Attitudes towards deprescribing in geriatric psychiatry: A survey among older psychiatric outpatients. Basic Clin Pharmacol Toxicol2024;134(1):97–106; doi: 10.1111/bcpt.13952
45.
MothAE, HølmkjærP, HolmA, et al.What makes deprescription of psychotropic drugs in nursing home residents with dementia so challenging? A qualitative systematic review of barriers and facilitators. Drugs Aging2021;38(8):671–685; doi: 10.1007/s40266-021-00875-1
46.
Robbins-WeltyGA, ShalevD, RiordanPA, et al.Top ten tips palliative care clinicians should know about the physical manifestations of psychiatric illness and treatment. J Palliat Med2024;27(11):1531–1540; doi: 10.1089/jpm.2024.0131
